{"filing":{"accession_number":"0001104659-26-066021","cik":"0001650664","ticker":"EDIT","company_name":"Editas Medicine, Inc.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"tm2615565d2_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1650664/000110465926066021/tm2615565d2_8k.htm"},"events":[{"id":8955,"run_id":7861,"accession_number":"0001104659-26-066021","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Editas suspended and terminated its prospectus supplement for an at-the-market (ATM) offering program with TD Cowen, effectively halting its ability to raise capital through this mechanism without filing a new prospectus. The company had previously raised $43.9 million through this program. While this is a material event affecting the company's financing flexibility, it does not fit neatly into the standard taxonomy—it is neither a dilutive issuance (which describes the sale itself) nor a delisting risk, but rather a suspension of an existing capital-raising program that would materially impact investor assessment of the company's liquidity and financing options.","company_name":"Editas Medicine, Inc.","ticker":"EDIT","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1417,"accession_number":"0001104659-26-066021","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Editas suspended and terminated its prospectus supplement for an at-the-market (ATM) offering program with TD Cowen, effectively halting its ability to raise capital through this mechanism without filing a new prospectus. The company had previously raised $43.9 million through this program. While this is a material event affecting the company's financing flexibility, it does not fit neatly into the standard taxonomy—it is neither a dilutive issuance (which describes the sale itself) nor a delisting risk, but rather a suspension of an existing capital-raising program that would materially impact investor assessment of the company's liquidity and financing options.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:07:20.384859+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1417,"accession_number":"0001104659-26-066021","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Editas suspended and terminated its prospectus supplement for an at-the-market (ATM) offering program with TD Cowen, effectively halting its ability to raise capital through this mechanism without filing a new prospectus. The company had previously raised $43.9 million through this program. While this is a material event affecting the company's financing flexibility, it does not fit neatly into the standard taxonomy—it is neither a dilutive issuance (which describes the sale itself) nor a delisting risk, but rather a suspension of an existing capital-raising program that would materially impact investor assessment of the company's liquidity and financing options.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:07:20.384859+00:00","company_name":"Editas Medicine, Inc.","ticker":"EDIT","filing_date":"2026-05-26"}]}